Valuation, page-17

I bought into SPL 2 years ago, because I thought I saw repetitive revenue (vivagel) coming and it has but what a disappointment that the flow/size of the revenue has not increased at the rate I was anticipating. I also bought into SPL because of the DEP drug platform, which they supposed to license out after the phase 2 trial that was about to be completed (that was 2 years ago). Here we are, the Patent is expiring yet we are adding new combination treatments into the monotherapy trial so to delay the release of the result? Time for SPL to regain our trust and fulfil their promise by releasing the result of the DEP-Dox trial, Even If there is NO INTERESTED BUYER of the drug, at least SPL will regain respect from its shareholders.

I hate it when they drip-feed us 1 case study at a time whenever JF presents. As @Aristarchus said, they raise investors money to slowly burn through it to do science and fame and apear on television, but have yet to earn 1c as dividend/return to the investors. Disappointing